Skip to content

Nurix Therapeutics

US · NRIX #2679 by market cap Listed 2020
12.85 -0.75 -5.51%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 13.16 -3.24%
After-hours 12.85 0.00%
Overnight 13.49 -0.81%
27.7912.8512.852026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on NRIX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -34.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 17.3% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation B-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 5.3x Better than 96%
Price / Sales 2.4x Better than 51%
P/E vs own 5-yr range 98th pctl Better than 5%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Operating margin -340.2% Better than 5%
Net margin -314.9% Better than 4%
Return on equity -49.6% Better than 9%
Return on invested capital -49.8% Better than 6%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -51.9% Better than 5%
6-month return -26.6% Better than 21%
12-month return (ex latest month) 51.2% Better than 84%
Distance below 52-week high 54.5% Better than 15%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 7.0x Better than 91%
Debt to assets 8.1% Better than 73%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 174.9% Better than 93%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -16.99%
1M -50.77%
3M -52.50%
6M -21.74%
YTD -32.26%
1Y -16.18%
3Y +97.39%
5Y -59.00%

Key statistics

Price & volume

Prev close
13.60
Open
13.40
Day range
12.83 - 13.67
Avg price
13.00
Volume
2.43M
Turnover
31.64M
Amplitude
6.21%
52-week range
12.83 - 28.23

Valuation

P/E
-4.21
P/E (TTM)
5.29
P/B
1.45
EPS
-3.05
Net profit
-333.21M
Net assets
968.28M

Share structure

Market cap
1.40B
Float cap
1.12B
Shares out
109.25M
Float shares
87.20M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-07-24
52-week range 0% of range
12.83 28.23

54.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-14.99M net over the window

Short interest

Shares short
18.94M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Nurix Therapeutics (NRIX)?

Nurix Therapeutics last traded at 12.85. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Nurix Therapeutics's market cap?

About 1.40B.

What is the P/E ratio of Nurix Therapeutics?

The trailing twelve-month P/E is 5.29. The Valuation tab shows it against the stock's own five-year range.

Does Nurix Therapeutics pay a dividend?

Nurix Therapeutics does not currently pay a regular dividend.

Is Nurix Therapeutics a buy according to analysts?

The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 35.33, which implies 174.9% upside from the current price. This is not investment advice.

What is Nurix Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Nurix Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Nurix Therapeutics discussion 0 comments

Add a comment